Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2409 Target Snapshot

Bifunctional epoxide hydrolase 2 · SINGLE PROTEIN · Homo sapiens

3,074Compounds
274Assays
7Approved Drugs
3,654.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P34913. Start with chronic obstructive pulmonary disease, then reuse UniProt P34913 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic obstructive pulmonary disease, then reuse UniProt P34913 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
chronic obstructive pulmonary disease

Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug remains visible in the same block.

Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include GSK2256294. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional epoxide hydrolase 2 as ChEMBL target CHEMBL2409, mapped to UniProt P34913. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional epoxide hydrolase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2409
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P34913
Bifunctional epoxide hydrolase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional epoxide hydrolase 2 is the right protein anchor across sources, using UniProt P34913 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic obstructive pulmonary disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional epoxide hydrolase 2
UniProt AccessionP34913
Component TypeProtein
Sequence Length555 aa

Bifunctional epoxide hydrolase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional epoxide hydrolase 2, mapped to UniProt P34913. Sequence length is 555 aa.

Mapped IDP34913
Review nameBifunctional epoxide hydrolase 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease.

Clinical signal Phase I
chronic obstructive pulmonary disease
1 linked drug · 1 direct · 1 efficacy
Linked drugGSK2256294
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include GSK2256294. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic obstructive pulmonary disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
4
Phase III
9
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC503,396.0
KI235.0
EC5022.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3327073 10.7 Ki 0.02 Preclinical
CHEMBL3818875 10.57 IC50 0.027 Clinical
CHEMBL5190894 10.52 IC50 0.03 Preclinical
CHEMBL5425833 10.3 IC50 0.05 Preclinical
CHEMBL5746598 10.3 Ki 0.05 Preclinical
CHEMBL5891245 10.3 Ki 0.05 Preclinical
CHEMBL6038062 10.22 Ki 0.06 Preclinical
CHEMBL4752831 10.1 Ki 0.08 Preclinical
CHEMBL4745610 10.09 IC50 0.082 Preclinical
CHEMBL4781218 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

107
5.0
196
5.5
204
6.0
299
6.5
369
7.0
449
7.5
473
8.0
519
8.5
417
9.0
54
9.5
pChEMBL
Approved Drugs

Approved Drugs

REGORAFENIB
CHEMBL1946170
Approved 2012
SORAFENIB
CHEMBL1336
Approved 2005
FULVESTRANT
CHEMBL1358
Approved 2002
ZILEUTON
CHEMBL93
Approved 1996
Assay Landscape

Assay Landscape

274
Total Assays
2,893
Tested Compounds
2
Assay Types
Binding — 273 assays, 2,893 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 190 2,043 7.6
cell-based format 59 303 7.5
assay format 21 487 7.8
organism-based format 1 59 8.5
subcellular format 1 0
tissue-based format 1 1 8.2
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine